ClinicalTrials.gg

Program

Trifluridine

Also written as “Suvemcitug injection, trifluridine/tipiracil tablets”.

Its studies are mostly in Colorectal Neoplasms · Mycobacterium avium-intracellulare Infection, led by 3 companies.

Furthest: phase 3, since Nov 2, 19993 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Otsuka10 open or runningphase 1since May 24, 2013May 24, 2013none ahead
Simcere Pharmaceutical Group11 open or runningphase 3since Sep 30, 2025Sep 30, 2025Jan 2028phase 3 · NCT07361003

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: no phase study in Mycobacterium avium-intracellulare InfectionNew to AmgenAmgen · NCT00002037 · 15 enrolled · United States
  2. May 24, 2013Otsuka's first study: phase 1 study in Advanced Solid TumorsNew to OtsukaOtsuka · NCT01867866 · 44 enrolled · United States
  3. Sep 30, 2025Simcere Pharmaceutical Group's first study: phase 3 study in Colorectal NeoplasmsNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT07361003 · 464 planned · China

Ahead

  1. Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsSimcere Pharmaceutical Group · NCT07361003

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA inhibitor”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07361003Colorectal Neoplasms · China3RecruitingSimcere Pharmaceutical GroupJan 2028464
NCT01867866Advanced Solid Tumors · United States1CompletedOtsukaOct 201344
NCT00002037Mycobacterium avium-intracellulare Infection · United States–CompletedAmgen15

How it is read

Names in the registry

  • “Trifluridine”, 2 entries
  • “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.